Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like X*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000380	Xeris Pharmaceuticals, INC.	03/31/2023	71090000101	Keveyis Dichlorphenamide Oral Tablet 50 MG, 100 Each, Bottle	Brand	FDA	02/06/2023	2984.92	33135.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Keveyis was relabeled from 71090-0001-01 to 72065-0001-01 with an effective date of 12/15/2022. 72065-0001-01 is the NDC that will be used moving forward.
Rx0000380	Xeris Pharmaceuticals, INC.	03/31/2023	72065000101	Keveyis Oral Tablet 50 MG, 100 Each, Bottle	Brand	FDA	02/06/2023	2984.92	33135.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Keveyis was relabeled from 71090-0001-01 to 72065-0001-01 with an effective date of 12/15/2022. 72065-0001-01 is the NDC that will be used moving forward.
Rx0000380	Xeris Pharmaceuticals, INC.	09/30/2023	72065000301	Recorlev Oral Tablet 150 MG, 50 Each, Bottle	Brand	FDA	07/01/2023	1548.69	17854.00	03/02/2040	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None